A STEP FORWARD.
Context Therapeutics is dedicated to creating new medicines to treat hormone-responsive (HR+) cancers. We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis. Context’s lead program is Apristor® , an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast cancer.
Why HR+ Cancer?
Breast, prostate, and gastrointestinal cancers are poorly addressed and result in >100,000 deaths per year in the United States.
The rapid advances in the field of immune-oncology ("IO") have not trickled down to HR+ cancers.
The underlying drivers of HR+ cancer growth (hormones and their associated regulatory proteins) are well understood relative to other cancers.
THE UNMET NEED IN HR+ CANCERS
Most current antihormonals are dual agonist/antagonists. There is a need for pure antagonists.
Identification of novel drug targets beyond androgen receptor (AR) and estrogen receptor (ER).
A new generation (the "3rd Gen") of companies developing HR+ targeting agents has emerged to address this unmet need.
Context has developed proprietary reagents and tools to evaluate target engagement, pharmacodynamic response, and patient enrichment across disease states. Our goal is not only to develop new and effective drugs, but to identify those patients who are most likely to benefit.